Stock & Company Details
Incyte Corp. $INCY
Price:
N/A
N/A
203M
$23B
52 Week High:
N/A
10 Day Average Volume:
N/A
14.37
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
INCY technical indicators
Latest Incyte Corp. (INCY) indicator readings as of 2026-10-09.
INCY's 14-day RSI is 31.4, in neutral territory. At $112.79 it is trading 5.2% above its 200-day moving average of $107.21, and below its 50-day average of $122.61. Price sits near the lower Bollinger Band ($110.36 to $131.02). ADX reads 22.0, sitting between trending and range-bound.
INCY backtested strategy results
How 4 rule-based strategies performed on Incyte Corp. (INCY) over recent history, last backtested 2026-09-03. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +6.9% | 44% | 9 | -35.7% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -8.6% | 27% | 30 | -41.4% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -33.1% | 27% | 30 | -40.8% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +23.2% | 57% | 21 | -28.3% |
Overview
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Finance Bot
Ask your questions
Start by typing a question below.
